long intergenic non-protein coding RNA 1304Genealiases: []
Q-omics provides the consensus-scored LINC01304 profile across patient tissues and cancer cell-line models. LINC01304 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, LINC01304 is differentially expressed in 2, with the highest sampling consensus in THCA. Additionally, LINC01304 RNA expression shows 6,390 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight ACC, THCA, and STAD as cancer lineages where LINC01304 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01304 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01304 survival associations across molecular data types. LINC01304 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01304 RNA expression–survival associations across cancer types. High LINC01304 expression shows unfavorable associations in ACC, KIRC, BRCA, THCA and READ, but favorable associations in LUSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .005). Together, the overview and detailed table identify ACC as the clearest survival context for LINC01304 RNA expression.
This table summarizes LINC01304 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01304. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01304 shows lower tumor expression in THCA and BRCA. The THCA box plot shows higher LINC01304 RNA expression in normal versus tumor tissue (log2 FC = −0.013, t-test p = .002).
This table shows molecular features associated with LINC01304 in patient tissues and cancer cell lines. In patient samples, LINC01304 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
